Clinical Trial Update: Phase II Study of RAD001 Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase II study of RAD001 in head and neck cancer was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• RAD001 (everolimus)

Snippet

Sponsor: Julie E. Bauman, MD, MPH | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: TERMINATED | Results posted: 2017-12-19